Ergoteles’s Cardiff Oncology CRDF Stock Holding History

Ergoteles’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-184,000	Closed	-$405K	–	1616
2022 Q2	$405K	Buy	+184,000	New	+$308K	0.01%	939

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ergoteles's CRDF Position: Q3 2022 in Review

Ergoteles sold out of Cardiff Oncology (CRDF) in Q3 2022, closing a stake of 184,000 shares — an estimated $405K sold.

Ergoteles first reported a position in CRDF in Q2 2022 and held it in 1 quarter. The position peaked at $405K in Q2 2022. 58 funds tracked by Wall St. Rank hold CRDF as of Q3 2022.

Ergoteles reported no remaining Cardiff Oncology position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 184,000 Cardiff Oncology shares in Q3 2022, an estimated $405K.
Ergoteles first reported a position in Cardiff Oncology in Q2 2022 and held it in 1 quarter.
Ergoteles's Cardiff Oncology position peaked at $405K in Q2 2022.
58 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.